The aim of this study was to study interactions between stromal bone marrow microenvironment and leukemic cells. We tested the hypothesis that stromal cells prevent apoptosis of AML cells by up-regulating anti-apoptotic proteins in leukemic blasts. In HL-60 and NB-4 cells, serum deprivation-and ara-Cinduced apoptosis was diminished when cells were cocultured with murine MS-5 stromal cells (P Ͻ 0.02). This effect was reproduced with conditioned medium from MS-5 cells. Cocultivation with stromal cells induced Bcl-2 expression levels, both by PCR analysis and flow cytometry. In primary AML (n = 14), ara-C-induced apoptosis was significantly lower in cells cocultured with MS-5 cells than in controls (P Ͻ 0.001). This effect was partially preserved when leukemic cells were separated from stromal cells by a microporous insert (in 5/9 samples, P = 0.04). In addition, Bcl-2 levels were significantly higher in stroma-supported than in control CD34
Introduction
Growth and differentiation of most types of hematopoietic cells in vivo require direct contact with stroma cells. 1, 2 The importance of the hematopoietic microenvironment in the maintenance and differentiation of normal hematopoietic progenitors has been emphasized in long-term bone marrow cultures. 3, 4 However, the molecular mechanisms of the interaction between stromal and hematopoietic cells are not well defined. Nevertheless, it has been shown that stromal cells produce a variety of growth factors, and in some cellular systems, it has been observed that direct cell-cell contact is needed for cell growth and differentiation to occur. [5] [6] [7] Since leukemic cells originate from their normal counterparts and also reside within the bone marrow microenvironment, it is likely that stromal cells influence the proliferation and apoptosis of leukemic cells. This interaction may play a role in the resistance of residual, post-chemotherapy AML blasts to additional chemotherapeutic agents, a problem that remains a major hurdle in the treatment of AML. The cells that give rise to such leukemia cell regrowth must therefore originate from a compartment of cells that is relatively protected from cytotoxic agents ('survivor cells'). We hypothesize that the expression of apoptotic proteins in these surviving cells has a distinct profile, and that the expression of these proteins is regulated by stromal cells. This has been suggested in previous studies in which stromal cells were shown to prevent spontaneous or induced apoptosis in AML, 8 ALL, 9 and CLL 10 cells. In a recent study, the human bone marrow stromal cell line HS-5 improved AML cell survival in vitro and attenuated chemotherapy-induced cell killing. 11 This was further borne out in a prospective study of 70 childhood B-ALL cases, 12 in which the high recovery of ALL blasts in stroma-supported cultures was noted to predict a lower 4-year event-free survival rate (50% vs 91%). This study further suggested that protective signals within the stromal microenvironment maintain residual leukemic cells, leading to the recurrence of the disease. Although the nature of the stromal cellinduced changes in leukemic cells is poorly understood, several studies have suggested that the anti-apoptotic proteins may confer survival advantage on stroma-supported hematopoietic cells. [13] [14] [15] We therefore studied the role of stromal cells on the survival of leukemic cells using the murine stromal cell line MS-5, 16 which was shown to support primitive human progenitors [17] [18] [19] and a factor-dependent human leukemic cell line. 20 We especially focused on the role of Bcl-2 family proteins in protecting AML cells from ara-C-induced apoptosis. The results demonstrate that the anti-apoptotic effect of MS-5 stromal cells on HL-60 and primary AML cells is mediated by increasing Bcl-2 and Bcl-X L levels. We also observed an association of increased Bcl-2 expression levels in stroma-supported AML blasts in vitro with resistance to chemotherapy in vivo suggesting an important role for Bcl-2 in the survival advantage of the leukemic cells exposed to cytotoxic stress.
Materials and methods

Cell lines
The mouse stromal cell line MS-5 was kindly provided by Dr K Itoh. 16 MS-5 stromal cells are now routinely used for longterm support of primitive hematopoietic progenitors. 21, 22 The myeloid HL-60 cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). In some experiments, NB4 cells kindly provided by Dr M Lanotte 23 were used.
All cell lines were cultured in alpha-minimum essential medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% L-glutamine, and penicillin-streptomycin at 37°C in 5% CO 2 in a humidified incubator. The HL-60 cell number was adjusted to a starting concentration of 3 × 10 5 cells/mL. HL-60 cells were cultured in 24-well, flat-bottom plates with and without a confluent MS-5 stromal layer. In some experiments, cells were grown in serum-free conditions for 96 h, or they were treated with 1 M ara-C to induce apoptosis.
To study the effects of soluble factors produced by MS-5, conditioned medium of MS-5 cells (1 week old) was added to the leukemic cells at a final concentration of 30%. After this, the HL-60 cells were cultured for 96 h in 35-mm dishes. Experiments were done in duplicate in complete culture medium or under serum-free conditions.
Human subjects
Samples of bone marrow or peripheral blood for in vitro studies were obtained from 14 patients with newly diagnosed or recurrent AML with a high (Ͼ70%) blast count after obtaining informed consent following institutional guidelines. Two of the 14 patients had a previous history of myelodysplastic syndrome (refractory anemia), and three patients had undergone chemotherapy for other malignancies (breast cancer in two patients and prostate cancer in one). Mononuclear cells were separated by Ficoll-Hypaque (Sigma, St Louis, MO, USA) density-gradient centrifugation. The AML mononuclear cells were seeded at a concentration of 5 × 10 5 cells/ml. Cells were cultured in complete medium (alpha-minimum essential medium with 10% fetal calf serum) in the presence or absence of a confluent MS-5 stromal layer. In experiments comparing direct contact to noncontact conditions, AML cells were plated in 12-well plates containing MS-5 monolayers, either in direct contact or separated by a 0.4-m porous transwell insert (Corning, Corning, NY, USA) that allows passage of soluble growth factors.
Detection of apoptotic cells and cell kinetic studies
Cell cycle kinetics was determined by staining cells with acridine orange to determine the cellular DNA and RNA content by flow cytometric analysis. This method discriminates among cells in the G 0 , G 1 , S and G 2 M phases and shows the mean RNA content per cell during each phase of the cell cycle. 24 Briefly, 80 l aliquots of cells were mixed with 100 l of solution containing 0.1% (v/v) Triton X-100, 0.05 mol/l HCl, 0.15 mol/l NaCl, and 8 g/ml acridine orange (Polysciences, Warrington, PA, USA). Cell fluorescence was measured within 5 min of staining using the logarithmic scale of the FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) with 488-nm excitation of a 15-mW argon laser and filter settings for green (530 nm) (DNA) and red (585 nm) (RNA) fluorescence. Ten thousand events were stored in list mode for analysis. The percentage of cells in the 'sub G 1 region' defined the proportion of apoptotic cells in the tested populations. Cell debris was defined as events in the lowest 10% range of fluorescence, and events in this region were excluded from analysis. The percentage of cells in S-and G 2 M was determined using ModFit software (Verity Software House, Topsham, ME, USA).
In experiments comparing direct contact to noncontact conditions, AML cells were washed and resuspended in binding buffer containing Annexin V (Roche Diagnostic, Indianapolis, IN, USA). Cells were counter-stained with CD45 PE (PharMingen, San Diego, CA, USA), or respective isotype control antibody to exclude contamination of stromal cells and analyzed by flow cytometry. Annexin V binds to those cells that express phosphatidylserine on the outer layer of the cell membrane and is considered an early apoptosis marker. 25 
PKH-26 labeling
This method identifies the number of divisions an individual cell undergoes, as each daughter cell has half the PKH-26 membrane fluorescence of the parent cell. 26 Before cultures, HL-60 cells were labeled with PKH-26-GL (Sigma Immunochemicals) as per the manufacturer's instructions and as previously described. 27 Briefly, cells were suspended in 1 ml of diluent and immediately transferred into a polypropylene tube containing 1 ml of 4 × 10 −6 mol/l PKH-26 in diluent at room temperature. After 5 min of incubation with frequent agitation, 2 ml of FBS was added to the suspension for 1 min. Complete medium was added to bring the total volume to 8 ml, and the cells were washed three times in complete medium. After the first wash, cells were transferred to a new tube. After the third wash, cells were resuspended in complete medium and cultured with or without a stromal cell layer. The mean fluorescence intensity of PKH staining was measured on days 2 to 5. The instrument was set up using the same laser power and gains as those used to monitor with the fluorescent microspheres, and the voltage on the photomultiplier tube was adjusted until the modal intensity of standard microspheres was identical to that at time zero. The ModFit computer program (Sigma) was used to deconvolute the raw histogram data into peaks representing cell generations.
Quantitation of Bcl-2 protein by flow cytometry
Cellular Bcl-2 content was measured in conjunction with CD34 antigen expression in AML blast cells. Briefly, after staining with PE-conjugated anti-CD34 monoclonal antibody (HPCA-2; Becton Dickinson), cells were washed twice and fixed in 1% formaldehyde (Sigma) for 15 min on ice, followed by permeabilization with 0.1% Triton X in phosphate-buffered albumin (1% albumin, 0.1% NaN 3 ) for 10 min at 4°C. Cells were then washed in cold phosphate-buffered saline before being added to 10 l of FITC-conjugated anti-Bcl-2 or isotype IgG 1 monoclonal antibody (Dako, Carpinteria, CA, USA). Dead cells were gated out on the basis of their scatter characteristics (high side scatter and/or low forward scatter) and Bcl-2 expression was measured in the live cells. The intensity of Bcl-2-associated fluorescence was measured on a logarithmic scale. Bcl-2 expression was quantitated using Quantum Simply Cellular microbeads with QuickCal Software (Flow Cytometry Standard, Triangle Park, NC, USA), as previously described. 28, 29 Results were expressed as the antibody-binding capacity (ABC), which is an estimate of the number of antibody molecules bound per cell. 29 A FACScan flow cytometer equipped with an argon laser (488 nm) was used to measure fluorescence. For each sample, 10 000 cells were analyzed; cells were live-gated for CD34 positivity. Data were analyzed using Lysys software (Becton Dickinson).
RNA isolation and reverse transcription
RNA was isolated according to the single-step acid guanidinium thiocyanate-phenol-chloroform method. 30 Purified RNA samples were quantited using a DU-640 spectrophotometer (Beckman Instruments, Fullerton, CA, USA). A reversetranscription kit was used to synthesize cDNA, and this was done according to manufacturer's instructions (BoehringerMannheim, Indianapolis, IN, USA). One microgram of the total RNA template was used per 10 l of reverse transcriptase reaction. Bcl-X L and beta 2 -microglobulin primers were synthesized on an oligonucleotide synthesizer (model 392; Applied Biosystems, Foster City, CA, USA). Oligonucleotide primers (F, forward; R, reverse) used for expression analysis by RT polymerase chain reaction (PCR) were as follows: the human Bcl-X F 5Ј-AGTTTGAACTGCGGTACCGGC-3Ј (nucleotides 421-441) and R 5Ј-GAACCAGCGGTTGCGTTCCT-3Ј (nucleotides 754-776); the expected PCR product for Bcl-X L is 356 bp. Primers for ␤ 2 -microglobulin were F 5Ј-ACCCCCACTGAAAAAGATGA-3Ј and R 5Ј-TATCTTCAAA CCTCCATGATG-3Ј. Amplification and detection were performed using 32 P-dCTP incorporation. PCR was performed for 30 cycles. The radioactive products were detected on a Betascope 603 (Betagen, Waltham, MA, USA), after the gel was exposed to Kodak film.
Real-time quantitative RT-PCR
Duplicate samples of 1 l of each cDNA were used as templates by using the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems). We used the program Primer Express (Perkin Elmer) to design the primers and the probe for Bcl-2. Bcl-2 primers: F 5Ј GAGGAGCTCTTCAGGGACGG 3Ј and Bcl-2 R 5Ј GGTGCCGGTTCAGGTACTCA 3Ј. Fluorogenic TaqMan probe (FAM-labeled 5Ј AGGATTGTGGCC TTCTTTGAGTTCGGTG 3Ј) was added to the PCR mixture to a final concentration of 200 nM. GAPDH primers: F 5Ј GAAGGTGAAGGTCGGAGTC 3Ј and GAPDH R 5Ј GAA-GATGGTGATGGGATTC 3Ј; GAPDH TaqMan probe JOE-labeled 5Ј CAAGCTTCCCGTTCTCAGCC 3Ј (Perkin Elmer). Amplification conditions were as follows: 50°C for 2 min, 95°C for 10 min, then 40 cycles at 95°C for 15 s and 60°C for 60 s. GAPDH co-amplified with Bcl-2 was included as internal control for normalization of the variable content of human cDNA in each sample.
The PCR cycle number that generated the first fluorescence signal above a threshold (the threshold cycle (C T )) was determined. The threshold was calculated by the software as a value that is 10 standard deviations above the mean fluorescence generated during the baseline cycles. C T values are predictive of the quantity of input target; thus, the larger the amount of PCR product, the lower the C T . A comparative C T method detected relative gene expression. 31 Amplicons were run as duplicates in separate tubes to permit quantification of Bcl-2 gene normalized to a control, endogenous gene, GAPDH. The following formula can be used to calculate the relative amount of Bcl-2 in the sample (X), normalized to endogenous reference (GAPDH) and relative to the amount of Bcl-2 in another sample (Y): 2
−⌬⌬CT
, where ⌬C T is the difference in threshold cycles for Bcl-2 and GAPDH, and ⌬⌬C T for sample X = ⌬C T,X − ⌬C T,Y .
Statistical analysis
Results are expressed as the mean ± standard error of the mean. Statistical significance was determined by Student's two-tailed t-test and Mann-Whitney nonparametrical analysis using Statistica statistical analysis software (Statsoft, Tulsa, OK, Leukemia USA). A P value of Ͻ0.05 was considered statistically significant.
Results
Murine stromal MS-5 cells prevent serum deprivationinduced apoptosis and inhibits ara-C-induced apoptosis in HL-60 cells
To investigate the effect of stromal (MS-5) cells on the apoptotic potential of HL-60 cells, DNA fragmentation in apoptotic cells was measured by flow cytometry on the basis of differential staining with acridine orange ('sub G 1 region'). Specifically, HL-60 cells were cultured for 3 days in the absence of serum. After permeabilization, cells were stained with acridine orange and analyzed by flow cytometry. The percentage of apoptotic HL-60 cells increased to 29% and 38.8% on days 2 and 3, respectively. In contrast, only 4.6% and 5.3% of cells, respectively, grown in the presence of stroma exhibited apoptotic features ( Table 1 ). The percentage of apoptotic cells in the untreated cultures did not exceed 2% (data not shown).
MS-5 cells also partially prevented ara-C-induced apoptosis in HL-60 cells: following treatment with 1 M ara-C, massive induction of apoptosis occurred, while apoptosis was reduced by approximately 50% in cells grown on stroma (Table 1) . The experiments were repeated twice and yielded essentially identical results. While ara-C decreased cell numbers in control cultures (starting concentration 3 × 10 5 cells/ml, ara-C day 2-0.82 × 10 5 cells/ml, day 3-0.13 × 10 5 cells/ml), only a slight decrease was observed in HL-60 cells co-cultured with stroma (2.6 × 10 5 and 2.3 × 10 5 cells/ml, days 2 and 3, respectively). These data suggest that stroma indeed maintains the viability of leukemic cells exposed to ara-C.
The anti-apoptotic effect of MS-5 is independent of direct cell-cell contact
To distinguish the role of direct cell-to-cell contact from the effect of potential soluble factors produced by stromal cells, we conducted experiments using MS-5 conditioned medium. In three experiments, conditioned medium collected from MS-5 cells was added to the culture medium at a concentration of 30%. In HL-60 cells, conditioned medium reduced the rate of serum-deprivation-induced apoptosis from Ͼ80% to 6.2% Table 1 Effect of co-culture of HL-60 and stromal MS-5 cells on apoptosis
Serum withdrawal
Ara-C (1 M) on day 3 ( Table 2 ). The same effect was observed in NB4 cells: both MS-5 cells and CM were able to protect NB4 cells grown in the absence of serum. The number of HL-60 and NB4 cells increased when cells were co-cultured with MS-5 or MS-5 conditioned medium was present, while it decreased in controls ( Figure 1 ).
MS-5 stromal layer induces expression of antiapoptotic Bcl-2 protein in HL-60 cells
Because of the potential role of Bcl-2 protein in regulating programmed cell death, and because of our observation that stromal cells prevent serum-deprivation-or ara-C-induced apoptosis in HL-60 cells, we investigated whether stromal cells regulate Bcl-2 expression. RNA was isolated from HL-60 cells cultured without serum or treated with ara-C, with or without MS-5 cells, for 48 h. To overcome potential shortcomings of the semi-quantitative RT-PCR, we developed a real-time PCR assay for Bcl-2 expression. The PCR amplification plot showed lower C T values (higher expression) for Bcl-2 in HL-60 cells co-cultured with MS-5 cells compared to control samples exposed to ara-C or serum withdrawal (ara-C, 26.09 ± 0.42 vs 28.05 ± 0.25; serum withdrawal, 23.33 ± 0.13 vs 26.38 ± 0.67, Figure 2a ). C T values for GAPDH were identical assuring equal amount of cDNA template used. Using the comparative C T method, Bcl-2 mRNA levels were determined to be 6.8-fold higher in HL-60 cells cocultured with MS-5 in serum-free medium as compared with controls, and 1.7-fold higher following ara-C exposure. No difference was observed in Bcl-X expression levels (data not shown). We then applied quantitative flow cytometry to determine Bcl-2 protein levels. As expected, we found significantly increased Bcl-2 protein levels in cells cocultivated with MS-5 compared with baseline controls and to cells cultured in the absence of MS-5: Bcl-2 protein baseline levels were 81.7 × 10 5 ABC/cell, which remained unchanged under serum-free conditions (84 × 10 5 ABC/cell) and increased to 269 × 10 5 ABC/cell in cells grown on MS-5 stroma (Figure 2b ). When cells were treated with ara-C, the surviving cells without stromal support showed only minimally increased Bcl-2 levels (94. 
Stromal cells decrease the proliferation of leukemic cells
The effect of stroma on the proliferation of HL-60 cells grown in the presence of serum was tested by analysis of cell cycle and cell division growth. Leukemic cells were cultured for 5 days in the presence or absence of MS-5 stromal cells. On day 5, HL-60 cell numbers were significantly lower for HL-60 cells cultured on a stromal layer (0.5 × 10 6 /ml) than for controls (1.5 × 10 6 /ml). No significant changes in cell-cycle distribution were seen in control cells, but the percentage of proliferating (S + G 2 M) cells was decreased in HL-60 cells grown in the presence of a stromal layer on day 3 (45.3% vs 58.9%) and remained decreased on day 4 (41% vs 50%, see Table 3 ). In NB4 cells, the percentage of S/G 2 M cells was also lower in cells growing on the stromal layer compared to controls (day 1, 52.8% vs 67%; day 2, 45.6% vs 64.8%). The addition of conditioned medium (CM) slightly decreased the percentage of proliferating cells in both HL-60 and NB4 cells.
The inhibition of proliferation of HL-60 cells by MS-5 was confirmed when actual cell divisions were studied using the fluorescent membrane dye PKH-26GL, which binds irreversibly to cell membranes and is then equally partitioned between daughter cells in mitosis. Specifically, on days 2, 3 and 5, the PKH-26GL mean fluorescent channel was lower in control cells (227.9, 130.78 and 57.29, respectively) than in stromacocultured cells (268.21, 151.02 and 92.11), indicating decreased proliferation of the HL-60 cells after contact with stroma ( Figure 3) . On the basis of PKH-26GL fluorescence analysis, we calculated the number of cell divisions using the Cell Proliferation Model software. Histogram deconvolution showed that only 11.9% of control cells were fourth generation and 85.8% were fifth generation on day 5; whereas among stroma-supported cells, 35.4% were capable of four divisions and only 63.1% of five divisions.
MS-5 stromal cells prevent ara-C-induced apoptosis in primary AML cells
Next, we examined the effect of stromal cells on ara-Cinduced apoptosis in leukemic cells from patients with pri- mary AML. The patients' characteristics are summarized in Table 4 . Primary AML cells were growing at the periphery or on top of the stromal cells ( Figure 4 ) and could be easily separated from stromal cells by washing. Since less than 1% of leukemic cells were detected in the trypsinized stromal layer by CD45 flow cytometry analysis, apoptosis and Bcl-2
Leukemia expression were studied in the nonadherent fraction in all experiments. Bone marrow mononuclear cells from the AML patients were treated with 1 M ara-C for 2 days, and the percentage of apoptotic 'sub G 1 ' cells was determined by flow cytometry after staining with acridine orange. As shown in Table 5 , ara-C-induced apoptosis in stroma-supported AML blasts was significantly lower than that of control cells for all patients studied (13.2 ± 4.8% vs 37.5 ± 7.4%; P Ͻ 0.001). Examples of flow cytometric results are shown in Figure 5 . While the total AML cell number after co-culture with MS-5 in the presence of ara-C was not higher compared to controls, non-apoptotic cell number (assessed as absolute number of non-subG 1 cells) was significantly higher when AML cells were co-cultured with MS-5 stromal cells (2.4 ± 0.5 vs 1.6 ± 0.4 cells/ml, P = 0.004).
In samples from a subset of patients, we performed cellcycle analysis after 2 days of culture with ara-C. The percentage of AML blasts in the S and G 2 + M phases ranged from 0.8% to 11.5% in controls and from 0.4% to 31.86% in stroma-cocultured cells (Table 5) . Although the mean percentage of AML blasts in S + G 2 M was higher for cells cultured on the stromal layer than for control cells, the differences were not statistically significant (7.7 ± 3.3% vs 3.4 ± 1.1%; P = 0.08, Table 5 ).
To determine if inhibition of ara-C-induced apoptosis occurs independent from direct cell-to-cell contact in primary Cell tracking by PKH-26-GL labeling of HL-60 cells. HL-60 cells were labeled with PKH-26-GL and analyzed on day 0, after which they were maintained in culture for 5 days in the presence or absence of stromal cells, as described in Materials and methods. On day 5, cells were harvested and analyzed by flow cytometry. The three histograms are generated from the deconvolution of PKH-6 fluorescence by the ModFit program, representing a parental population on day 0 (first panel, channel number 185) and daughter populations on day 5 (fourth generation, channel number 130 and fifth generation, channel number 110). AML samples, we then compared the effects of AML/MS-5 in direct co-culture or in culture with porous transwell inserts (TW). In nine AML samples, 81.3 ± 8.0% cells were apoptotic as determined by annexin-V-positivity following ara-C exposure. In conditions of direct cell-to-cell contact, only 32.5 Table 5 Effect of MS-5 stromal cells on apoptosis and proliferation of AML blasts after ara-C treatment (48 
Results are the percentage of apoptotic subdiploid cells and proliferating cells, which was determined by flow cytometric analysis of acridine orange-stained cells as described in Materials and methods. ND, not done.
Figure 5
Flow cytometric analysis of apoptosis induced by ara-C in primary AML cells cultured alone or on the stromal layer. AML blasts were incubated in the presence of 1 M ara-C for 48 h. Apoptotic cells (cells in the subG 1 region) were detected on the basis of DNA fragmentation. Leukemia ± 7.0% cells expressed PS on the cell surface (P Ͻ 0.0001). In 5/9 AML samples, cells separated by TW were protected from ara-C cytotoxicity, albeit to a lesser degree compared to cells in direct contact with stroma (51.2 ± 12.6%, P = 0.04). Examples of CD45/annexin V expression are shown in Figure  6 . In the remaining four samples, while direct stromalleukemia cell contact protected from ara-C killing, no effect was observed when leukemic cells were separated by TW. Thus, direct cell-to-cell contact appears to be required for maximal anti-apoptotic effects in primary AML samples.
MS-5 stromal layer induces expression of antiapoptotic genes Bcl-2 and Bcl-X L in CD34
+ AML cells treated with ara-C
CD34
+ AML blasts from the 14 patients with AML were studied using flow cytometry to determine Bcl-2 levels. Baseline Bcl-2 levels varied, ranging from 4. Figure 7 .
We also measured Bcl-X L mRNA expression in AML blasts cultured with ara-C in the presence or absence of a stromal layer. Examples of PCR results are shown in Figure 8 . In five of the seven AML samples tested, Bcl-X L expression was higher in the cells supported by stromal cells than in control cells. 
Figure 7
Increase in Bcl-2 expression in ara-C-treated AML cells cultured on stromal cells. Bcl-2 expression was determined by quantitative flow cytometry after gating on the live CD34 + cells, as described in Materials and methods. Each histogram displays the Bcl-2 fluorescence (dark) and the fluorescence the isotype-matched control. The data show the emergence of a population with higher Bcl-2 expression in AML cells co-cultured with MS-5 stromal cells.
Figure 8
Expression of the mRNA for Bcl-X L in ara-C-treated AML cells cultured alone or in the presence of MS-5 stromal cells. Amplification and detection were performed using 32 P-dCTP incorporation, as described in Materials and methods. The figure shows AML sample exhibiting a higher Bcl-X L expression in stroma-supported leukemic blasts.
Bcl-2 expression in AML blasts cultured on MS-5 cells in vitro correlates with response to chemotherapy in vivo
We then compared the changes in Bcl-2 expression in CD34 + AML cells cultured in the presence or absence of stromal cells and examined this in light of the response to induction chemotherapy in vivo. All patients were treated with highdose ara-C in combination with idarubicin or topotecan according to MDACC protocols. Of the 14 patients studied, five achieved complete remission, six patients were resistant, and three patients died during induction therapy. Patients who died during induction therapy were excluded from analysis.
Response to therapy significantly correlated with age (P Ͻ 0.05). However, no statistically significant correlation was found between response to therapy, FAB-type (P = 0.74), or cytogenetics (P = 0.74). Baseline Bcl-2 expression was slightly higher in patients resistant to induction chemotherapy as compared to those who were sensitive (98.6 ± 45.8 vs 54.2 ± 22.5 × 10 3 ABC/cell; P = 0.37), but was considerably increased in stroma-cocultured AML cells obtained from patients who were later found to be resistant to chemotherapy (237.5 ± 119.72 × 10 3 ABC/cell; P Ͻ 0.05), while only a marginal increase in Bcl-2 expression was seen in samples from patients who achieved complete remission (64.0 ± 5.2 × 10 3 ABC/cell; P = 0.5) (Figure 9 ).
Discussion
We studied the effects of stromal cells on AML cell survival in the myeloid leukemia cell lines HL-60 and NB-4 and in primary AML samples. As a model for the hematopoietic/stromal cell interaction we used the murine stromal cell line MS-5, which was shown to be capable of supporting human hematopoiesis. This approach eliminated potential heterogeneity inherent in allogeneic human bone marrow stromal cells from different individuals. The MS-5 stromal cell line has recently been used for in vitro support of very early human progenitors, 19 and results have confirmed that MS-5 cells possess properties similar to those of human stromal cells. An additional advantage of MS-5 cells is that they can be easily propagated in tissue culture.
First, we tested the ability of MS-5 cells to prevent apoptosis in the myeloid leukemia cell lines HL-60 and NB-4 and in primary AML samples. In the absence of serum HL-60 and NB-4 cells rapidly underwent apoptosis, as demonstrated by the emergence of cells with sub-G 1 DNA content in flow cytometric assays. In both experiments, cell death was significantly delayed in cells grown in co-culture with stromal cells. MS-5 cells also reduced ara-C-induced apoptosis in HL-60 cells and in all primary AML samples tested. This observation confirmed results of previous studies that convincingly demonstrated the ability of stromal cells to regulate the survival of leukemic cells.
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Figure 9
The Bcl-2 protein level in cells from patients with AML. The Bcl-2 level was measured by flow cytometry in AML CD34 + cells, as described in Materials and methods, and was highest in AML cells from patients resistant to chemotherapy after culture on MS-5 stromal cells. The bars represent the mean values ± s.e.m. for the antibodybinding capacity (ABC) per cell for the test samples, which was calculated using standard microbeads. CR, complete remission.
We then examined the effects of direct stromal contact and of conditioned medium derived from MS-5 cells on the survival of leukemic cells. Stromal cell-conditioned medium was able to maintain the survival of HL-60 and NB4 cells in serumfree conditions, and no difference in the viability of cells was seen compared with cells grown in direct contact with stroma cells. These results suggest a role for soluble factors, rather than cell-to-cell contact, in the proliferation and survival of leukemic cells, at least in the model used. Such a role for diffusible molecules produced by MS-5 cells has been repeatedly demonstrated in different experimental systems 20, 32, 33 and the activity has been attributed to the effects of mouse stem cell factor (mSCF), mouse granulocyte colonystimulating factor, 33 thrombopoietin (TPO), 34 and nerve growth factor. 20 In our experiments, however, substituting MS-5 with recombinant TPO did not prevent ara-C-induced cell death in the leukemic cells (data not shown), suggesting the involvement of other growth factor(s). 32, 35, 36 Cytokines are known to play a major role in regulating leukemic cell proliferation, survival and apoptosis. In the bone marrow, they are provided either by direct contact with marrow stroma or are secreted into the microenvironment. Furthermore, ␤1 and ␤2 integrins, 37 as well as the adhesion receptors CD31 38 and c-kit 39 were shown to be involved in the homing of leukemic cells to the bone marrow niches. In the study of Bendall and coworkers, 8 the frequency of apoptosis was significantly greater in AML cells separated from LTMC marrow than in cells grown in direct contact with stroma. In contrast, a recent study by Nishihara and colleagues 18 demonstrated the importance of direct cellular contact with the stroma for the growth of progenitor B cells supported by MS-5, and a recent study favored the requirement of direct stroma-leukemia cell contact for protection from apoptosis of AML cells. 11 When primary AML cells were separated from stromal cells by microporous insert, an antiapoptotic effect was observed in 5/9 samples in our study, albeit to a lesser degree compared with direct leukemia-stromal contact. These data demonstrate heterogeneity between AML samples and suggest that direct cell-to-cell contact is necessary for maximal anti-apoptotic effects in primary leukemic cells, but not in leukemic cell lines. The ability of MS-5 stromal cells to synthesize different heparan sulfate proteoglycans that may bind distinct growth factors 40 could constitute an additional mechanism by which the stroma supports these cells. Alternatively, proteoglycans could be secreted by stromal cells and function as co-receptors for growth factors, a mechanism that was described recently for the binding of tumor growth factor-␤ (TGF-␤) to its receptor. 41, 42 Whether leukemic cells have different stroma requirements than normal progenitors is not known.
MS-5 cells were recently identified as the major producer of a chemotactic factor termed stromal-derived factor-1 (SDF-1), a member of the CXC subfamily of cytokines. 43 SDF-1 and its receptor CXCR4 play a critical role in the homing of normal progenitors to the bone marrow microenvironment, as demonstrated by lethality and lack of marrow hematopoiesis in CXCR4 knock-outs. [44] [45] [46] Considering that the majority of AML progenitors express CXCR4, 47, 48 the migration of these progenitor cells towards stromal cells and their subsequent interaction with membrane-bound cytokines could be another mechanism involved in the supportive role of MS-5 cells. Interestingly, however, following coculture with stromal cells, the expression of CXCR4 decreased on CD34 + cells from two AML samples studied (data not shown). This phenomenon was also observed for normal hematopoietic progenitors and for T Leukemia cells and is presumably due to ligand-induced internalization of the CXCR4 receptor. 49 Furthermore, another study showed that the expression of c-kit was reduced in TF-1 and MO7e cells following interaction with stroma cells, despite the finding that the mSCF/c-kit interaction was essential for the stroma-induced proliferation of the TF-1 cells. 50 Thus, downregulation of receptors vital for the migration and adhesion of leukemic cells would maintain a delicate balance between adherent and circulating leukemic cells in vivo and perhaps select resistant progenitors residing within bone marrow microenvironment niches.
Co-culture with MS-5 cells markedly inhibited ara-Cinduced cell death in all primary AML samples tested. Specifically shown by quantitative flow cytometry, Bcl-2 expression of leukemic progenitor cells was consistently higher in the presence of stromal cells than it was in the same cells and conditions in suspension cultures. Since the Bcl-2 histograms were strictly unimodal without evidence for a preexisting subpopulation of cells with higher Bcl-2 expression, this suggests that stroma up-regulates Bcl-2 expression in AML blasts. Bcl-X L expression was also found to be higher in the majority of AML cells cultured in the presence of stroma after ara-C treatment, thereby conferring additional cytoprotection. However, no significant changes were seen in the number of proliferating cells in AML in the presence or absence of stromal cells, suggesting that the anti-apoptotic function is more important in maintaining the survival of leukemic progenitors than in promoting their proliferation. However, the low proliferation of leukemic cells could also be the result of ara-C exposure than of their contact with stroma.
The perhaps most intriguing observation was the correlation of changes in Bcl-2 expression under the influence of the stromal cells in vitro with the response to chemotherapy in patients. Ara-C treatment in suspension cultures did not result in increased Bcl-2 expression. In the presence of stromal cells, Bcl-2 expression levels rose only marginally in patients who responded to chemotherapy. In contrast, a dramatic increase in Bcl-2 levels was observed in patients resistant to chemotherapy. This finding could explain the discrepancy with a report by Garrido et al, 11 where inhibition of apoptosis of AML cells by a human stromal cell line was reported not to be associated with increased Bcl-2 levels. However, an increase in Bcl-2 was observed in a subset of patients (11/30 AML) in this study. It is conceivable that these patients were resistant to chemotherapy, but no clinical correlates were reported. In addition, Garrido et al used a human immortalized stromal cell line (HS-5) and cultured their cells in the presence of cytokines. Recently, primary bone marrow mesenchymal cells cultured in autologous plasma were reported to promote ALL cell survival, which was associated with increased Bcl-2 levels. 51 Because the Bcl-2 baseline levels were only slightly higher in the resistant, as compared to the sensitive group of patients, we infer that a major mechanism of resistance is induction of Bcl-2 in AML blasts. Our in vitro data using HL-60 cells support this conclusion: Bcl-2 histograms obtained on day 0 and following coculture with MS-5 are strongly suggestive of induction of Bcl-2 in HL-60 cells. Furthermore, the number of HL-60 cells cocultured with MS-5 in the absence of serum increased less than two-fold compared to baseline, ie the selection of a high Bcl-2 expressing subpopulation of HL-60 cells is unlikely. Additional experiments would be needed to elucidate the role of specific stromal cell-derived cytokines in the regulation of Bcl-2 family genes on leukemic cells.
The marrow stroma provides a range of regulatory signals essential for the survival, growth, and differentiation of normal Leukemia hematopoietic stem cells. [52] [53] [54] [55] It is becoming clear that acute leukemia cells are also dependent on exogenous factors for survival. As proof of this, there is considerable evidence that stromal cells can prevent serum-deprivation-induced and chemotherapy-induced apoptosis of leukemic cells in vitro. 8, 9, 56, 57 Such an influence of stroma cells on leukemia cell survival is likely to be critically relevant following induction chemotherapy in AML, when a small number of leukemic cells survive in the bone marrow. Therefore, a better understanding of the molecular mechanisms involved in stromal/leukemia cell interactions might lead to new therapeutic interventions in patients with minimal residual disease after conventional treatment.
Members of the Bcl-2 family regulate a distal step in the cell death pathway. Although its mechanism of action is still unclear, Bcl-2 and its homolog Bcl-X L function as suppressors of cell death that can be triggered by a variety of signals. [58] [59] [60] [61] [62] In AML, high Bcl-2 levels are associated with resistance to chemotherapy, decreased rates of complete remission, and shortened survival. [63] [64] [65] [66] [67] We investigated the possibility that stromal cells maintain the viability of myeloid leukemic cells by regulating Bcl-2 expression and found that after the induction of apoptosis, Bcl-2 mRNA levels were increased in stroma-supported HL-60 cells compared to control cells. These data are in agreement with those obtained from several studies showing that Bcl-2 is up-regulated in ELM-D, 14 Myl-D7 15 and DA-1 cells 68 in contact with MS-5 cells. Recently, it was demonstrated that Bcl-2 not only inhibits apoptosis, but also restrains cell-cycle entry [69] [70] [71] and that these two functions can be genetically dissociated. 72 In our study, the proliferation rate of HL-60 cells cocultured with stromal cells in the presence of serum was significantly lower than that in control cultures as demonstrated by a decreased cell count, cell cycle proliferation, and a diminished number of cell divisions as measured by PKH-26GL labeling. One can infer from this that stromal cells have a dual function in vivo: they prevent the cell death of leukemic cells and also inhibit their proliferation. 73, 74 This mechanism would also protect leukemic cells from apoptosis because proliferating cells are more vulnerable to apoptotic stimuli. We hypothesize that the induction of Bcl-2 expression by stromal cells could be responsible for this phenomenon. Indeed, we have observed overexpression of Bcl-2 and Bcl-X L in non-proliferating AML progenitor cells. 75 In conclusion, we observed anti-apoptotic effects of MS-5 stromal cells on HL-60, NB4 and primary AML progenitor cells that were mediated by Bcl-2 and Bcl-X L . These mechanisms may be an important component of the interactions between leukemic and stromal cells in vivo, since it has the potential of promoting chemoresistance in AML cells. The observed association of high Bcl-2 expression in stromasupported AML blasts in vitro with resistance to chemotherapy in vivo suggests that the same mechanisms are operational in vivo and in vitro. It also points to the crucial role of Bcl-2 in the survival of leukemic cells. Therefore, a combination of agents that target Bcl-2, such as ATRA, [76] [77] [78] anti-Bcl-2 oligodeoxynucleotides [79] [80] [81] and small-molecule Bcl-2/Bax inhibitors 82 could be useful adjuncts to currently available chemotherapeutic drugs. This concept is presently under investigation. 83 
